AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03743454 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention will be applied.
Study NCT02374684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methosulide
Description: Tolerability Study:~Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)~Pharmacokinetic Study:~Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg~,group 2:depending on the adverse drug reaction,150mg/250mg)~Food Effect on the Pharmacokinetics:~single dose(100mg),two status(Feeding and fasting), washout period(7 days)
Study NCT02374684 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match with experimental groups
Study NCT04445142 — intervention group
Intervention type: PROCEDURE
Intervention: fovea-sparing internal limiting membrane peeling
Description: fovea-sparing internal limiting membrane peeling surgery
Study NCT00879385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacogen™ (decitabine)
Description: Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).~Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs
Study NCT00879385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vectibix® (panitumumab)
Description: Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.~DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.~Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr
Study NCT01338337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
Study NCT01344915 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Locked knee brace
Study NCT04107714 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STC
Description: The peer-led and web-based group program contains four lessons plus one booster session:~* Lesson 1: Consider the pros and cons of disclosing: Participants reflect on their experience of self-stigma and weight their pros and cons of (non-)disclosing their child's mental illness.~* Lesson 2: Different ways to disclose: Participants learn about different ways to disclose and their respective pros and cons. Afterwards participants discuss possible responses they might experience and develop strategies to cope with.~* Lesson 3: Communication about disclosure between parents and their child: Participants discuss pros and cons of (non-)disclosure for their children and how to negotiate whether to disclose or not.~* Lesson 4: Telling your story: Participants learn how to tell their own story.~* In a booster session, participants discuss their experiences with disclosure or non-disclosure.
Study NCT01046565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene cream 0.1%
Description: adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
Study NCT01046565 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adapalene lotion 0.1%
Description: adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
Study NCT00148759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r
Description: LPV/r 800/200 mg once daily
Study NCT00148759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r
Description: LPV/r 800/200 mg once daily
Study NCT02851303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine wean protocol as described in arm description
Study NCT02851303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Methadone wean protocol as described in arm description
Study NCT04064658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
Study NCT04064658 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic preconditioning
Description: Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by a sphygmomanometer placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
Study NCT04064658 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Encephaloduroarteriosynangiosis
Description: Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
Study NCT04064658 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Encephaloduroarteriosynangiosis
Description: Encephaloduroarteriosynangiosis is an indirect revascularization surgery of moyamoya disease
Study NCT03546621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex B
Description: 2 mg, once daily, subcutaneously
Study NCT03546621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex-B
Description: 5 mg, once daily, subcutaneously
Study NCT03546621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myrcludex-B
Description: 10 mg, once daily, subcutaneously
Study NCT03546621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
Study NCT03546621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir
Description: tenofovir disoproxil 245 mg, equivalent to tenofovir disoproxil fumarate 300 mg
Study NCT02313701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized visual presentation
Description: Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
Study NCT00646646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: sedative
Study NCT00646646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexmedetomidine
Description: Sedative
Study NCT00646646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: sedative
Study NCT00646646 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: saline placebo
Study NCT03776695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tyzivumab
Description: Tyzivumab Injection, (100 mg/5 mL/Vial), Zika Virus (ZIKV) Monoclonal Antibody (mAb)
Study NCT03776695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% Saline
Study NCT01984073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ER Niacin Oral Fat Challenge
Description: Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
Study NCT01984073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Niacin Oral Fat Challenge
Description: Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
Study NCT03074565 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic alone
Description: Sanative therapy using ultrasonic instrumentation alone
Study NCT03074565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic+
Description: Sanative therapy using ultrasonic plus hand instrumentation
Study NCT00226590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Induction Chemotherapy.
Study NCT00226590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
Study NCT00226590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
Study NCT00226590 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
Study NCT02394314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: MEDI0382 administered subcutaneously
Study NCT02394314 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously
Study NCT04143685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Oral administration of cytotec every 4 hours until a maximum of 6 doses
Study NCT04143685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Intravenous infusion of Pitocin through an IVAC until delivery
Study NCT01207375 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: memory retraining exercises
Description: Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
Study NCT01207375 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo control memory exercises
Description: Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
Study NCT01111708 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Close Rectal Dissection - IPAA
Description: Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
Study NCT01111708 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Close Rectal Dissection - IPAA
Description: Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
Study NCT03782519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis frequency reduction
Description: At initiation, frequency of dialysis will be reduced to 2 weekly sessions (incremental HD)
Study NCT03782519 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frailty diagnosis
Description: Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
Study NCT01984073 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Fat Challenge
Description: Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
Study NCT00561132 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vanadyl sulfate
Description: 50 mg twice daily orally for a period of 4 weeks
Study NCT03782519 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Frailty diagnosis
Description: Before randomization, we will determine whether patients are frail. We will define frailty as the presence of at least three of the following five conditions: malnourished according to dietitian assessment and/or short form of Mini Nutritional Assessment (MNA), grip strength and gait speed using participants' scores on the SF-36 Physical Functioning (PF) scale, exhaustion using in the quality of life questionnaire SF-36 vitality (VT) scale and physical activity according to patient assessment (one single question)
Study NCT03476135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACYW conjugate vaccine
Description: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine 0.5 mL, intramuscular
Study NCT01423968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide infusion
Description: Lipopolysaccharide 4 nanogram/kg body weight
Study NCT01423968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline
Study NCT01166841 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSVC line clamped
Description: A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
Study NCT04142034 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the iAmHealthy Behavioral Intervention
Description: iAmHealthy Behavioral Intervention Arm~Child/caregiver pairs in the iAmHealthy behavioral intervention arm will receive:~* usual care at their clinic for all issues, including overweight and obesity;~* a monthly newsletter that focuses on general child health. The child/caregiver pairs will receive six newsletters (one per month) during the six month intervention period (same newsletter provided to the newsletter-only intervention participants);~* weekly group sessions for the first three months, followed by monthly group sessions during the next three months, for a total of 15 group sessions. The trial's iAmHealthy behavioral intervention psychologist or social worker (one team per clinic) will deliver these group sessions via an electronic tablet that the trial sponsor will supply;~* 11 hours of individual homework sessions with the iAmHealthy behavioral intervention dietician
Study NCT04142034 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Newsletter only arm
Description: Newsletter arm participants will receive a monthly newsletter on maintaining a healthy weight through diet and exercise
Study NCT04142034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Consecutive Recruitment
Description: Recruitment of study participants through identifying potential participants through their medical records
Study NCT04142034 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Recruitment
Description: Recruitment of potential participants through flyers and advertisements
Study NCT00752700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional resistance training
Description: Conventional resistance training program (CRT)
Study NCT00752700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration resistance training
Description: Whole body vibration resistance training (WBV) on the FITVIBE-platform
Study NCT02146417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low pressure pneumoperitoneum
Study NCT02146417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal pressure pneumoperitoneum (12 mmHg)
Study NCT02146417 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block
Study NCT02146417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep neuromuscular block
Study NCT02675907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N1539
Study NCT02675907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo
Study NCT03360903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline
Study NCT03360903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate
Study NCT04002076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robot-assisted hand combined with occupational therapy
Description: Robot-assisted hand group contains 15 minutes of grasp and release motion, 15 minutes of visual feedback training and 30 minutes traditions occupational therapy. Traditional occupational therapy includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
Study NCT04002076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional occupational therapy
Description: Occupational therapy contains 60 minutes of traditional occupational therapy, which includes cognition training, sensory-motor function therapy, passive ROM exercise, functional hand training, activity of daily living skill training, instruction of using assistive devices,and so on.
Study NCT03291938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxidative Phosphorylation Inhibitor IACS-010759
Description: Given PO
Study NCT03291938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacodynamic Study
Description: Correlative studies
Study NCT03291938 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies
Study NCT03260179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL3810
Description: Fasting，oral ，4w on or 3w on/1w off
Study NCT00080665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
Study NCT00080665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202328
Description: Administered orally
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Administered orally
Study NCT02714569 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin
Description: Administered orally
Study NCT00334217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation
Description: PSS Cogrehab
Study NCT03008694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: pet/ct is used as radiotherapy simulation
Study NCT01713959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera System treatment
Description: Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
Study NCT01713959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulthera System treatment
Description: Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
Study NCT01713959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham treatment
Description: Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
Study NCT02953600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard Dose Spirulina Platensis
Description: As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
Study NCT02953600 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Zero Spirulina Platensis
Description: the zero pill-taken group is a comparison for two other groups.
Study NCT02953600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Double Dose Spirulina Platensis
Description: As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
Study NCT03633851 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric intraocular MX60T lens
Description: one eye will receive toric MX60T lens
Study NCT03633851 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard MX60 plus corneal incisions
Description: the other eye will receive standard MX60 lens with corneal incisions